Diagnostic challenges and treatment options for cutaneous T cell pseudolymphoma: A case study with rituximab treatment

Objective: Rare disease Background: Pseudolymphoma is a rare disorder that can mimic lymphoma both clinically and histologically. It usually af-fects middle-aged females. Since pseudolymphoma is a rare disorder not only is diagnosing the condition dif-ficult, but there is also a lack of standardized treatment guidelines. In the literature, anti-CD20 monoclonal antibody rituximab is described as an effective treatment option. Case Report: 46-year-old female fell ill suddenly with swelling and enlargement of her chin. Multiple skin biopsies were done, which were re-evaluated multiple times as well. Each ended with a new diagnosis for the patient. Finally, in the last revision of biopsy material, pseudolymphoma was confirmed. The patient received multiple courses of cor-ticosteroid treatments – locally and systemically – without long lasting effect. After diagnosis of pseudolym-phoma, the patient was started on intravenous rituximab and this treatment was effective. Conclusions: Cutaneous pseudolymphoma is a diagnostic challenge. Rituximab is a treatment option for refractory pseudo-lymphoma. Since there are no treatment guidelines for pseudolymphoma, more clinical studies are needed to establish best treatment options for these patients. Therefore, each reported clinical case is important.